Array
(
[Ovarian Cancer] => Array
(
[Austin] => https://www.survivornet.com/austin/
[Baltimore] => https://www.survivornet.com/baltimore/
[Charlotte] => https://www.survivornet.com/charlotte/
[Cleveland] => https://www.survivornet.com/cleveland/
[Columbus] => https://www.survivornet.com/columbus/
[Dallas / Ft. Worth] => https://www.survivornet.com/dallas-ftworth/
[Denver] => https://www.survivornet.com/denver/
[Detroit] => https://www.survivornet.com/detroit/
[Indianapolis] => https://www.survivornet.com/indianapolis-ovarian-cancer/
[Louisville] => https://www.survivornet.com/louisville/
[Memphis] => https://www.survivornet.com/memphis/
[Minneapolis] => https://www.survivornet.com/minneapolis/
[Nashville] => https://www.survivornet.com/nashville/
[Phoenix] => https://www.survivornet.com/phoenix/
[Portland] => https://www.survivornet.com/portland/
[Salt Lake City] => https://www.survivornet.com/salt-lake-city/
[San Antonio] => https://www.survivornet.com/san-antonio/
[San Diego] => https://www.survivornet.com/san-diego/
[San Francisco] => https://www.survivornet.com/san-francisco/
[San Jose] => https://www.survivornet.com/san-jose/
[Seattle] => https://www.survivornet.com/seattle/
) [Multiple Myeloma] => Array
(
[Ann Arbor] => https://www.survivornet.com/ann-arbor-michigan-multiple-myeloma-treatment/
[Miami] => https://www.survivornet.com/miami-florida-multiple-myeloma-treatment/
[Phoenix] => https://www.survivornet.com/phoenix-arizona-multiple-myeloma-treatment/
) [Glioma] => Array
(
[Midwest] => https://www.survivornet.com/midwest/
[Mountain States] => https://www.survivornet.com/glioma-mountain-states/
[Southeast] => https://www.survivornet.com/southeast/
) )
A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer Summary This study was designed to find out how effective and safe GW786034, is in the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer that has not responded to standard treatment.
View Eligibility Criteria Eligibility Criteria Inclusion criteria: Confirmed diagnosis of epithelial ovarian, fallopian tube or primary peritoneal carcinoma. Has received one prior platinum -based chemotherapy regimen(cisplatin,carboplatin, or oxaliplatin). Has psychological, familial, sociological or geographical condition that does not permit compliance with the protocol. Is on a specifically prohibited medication or requires these medications during treatment with GW786034. Exclusion criteria: Has had any surgery , chemotherapy, hormonal therapy, biologic, immunotherapy, or radiotherapy with in the last 28 days and has not recovered from such prior therapy. Poorly controlled hypertension(systolic 140mmHg or higher or Diastolic 90mmHg or higher). Currently taking warfarin. Low molecular weight heparin and low-dose warfarin(1mg per day)is permitted.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 10 Locations for this study
GSK Investigational Site Atlanta Georgia, 30342, United States
GSK Investigational Site Austin Texas, 78731, United States
GSK Investigational Site Bedford Texas, 76022, United States
GSK Investigational Site Dallas Texas, 75246, United States
GSK Investigational Site Fort Worth Texas, 76104, United States
GSK Investigational Site Randwick New South Wales, 2031, Australia
GSK Investigational Site Herston Queensland, 4029, Australia
GSK Investigational Site Melbourne , 3084, Australia
GSK Investigational Site Singapore , 11907, Singapore
GSK Investigational Site Singapore , 22989, Singapore
How clear is this clinincal trial information?
Sign Up Sign up now for access to powerful tools, top experts, and customized information to help you fight cancer.
Personalized content tailored to your profile and disease type Access exclusive patient guides Breaking treatment information and expert perspectives and more... Sign Up Now Already have an account? Sign In
Sign Up Already have an account? Sign In
Sign In Don't have an account? Sign Up
Password reset is unavailable because your account was created using 'Sign Up with Google. To continue, please use the Google sign-in button below. Don't have an account? Sign Up